<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020535</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00295926</org_study_id>
    <secondary_id>1R01AG069930-01</secondary_id>
    <secondary_id>R01AG069930</secondary_id>
    <nct_id>NCT05020535</nct_id>
  </id_info>
  <brief_title>Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)</brief_title>
  <acronym>BEACH</acronym>
  <official_title>Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) Phase 2a Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-patient phase 2a pilot study will assess the safety and tolerability of&#xD;
      MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-patient phase 2a pilot study will assess the safety and tolerability of&#xD;
      MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).&#xD;
&#xD;
      This study will monitor exploratory radiographic and clinical endpoints, explore the use of&#xD;
      biochemical biomarkers to demonstrate target engagement and biological response to a&#xD;
      potential new therapy targeted to neuroinflammation and synaptic dysfunction mechanisms.&#xD;
&#xD;
      MW189 is a novel small molecule drug candidate developed as a selective suppressor of&#xD;
      disease-and injury-induced proinflammatory cytokine overproduction associated with&#xD;
      destructive neuroinflammation/synaptic dysfunction cycles. In animal models of acute brain&#xD;
      injuries such as ICH and Traumatic Brain Injury (TBI), MW189 attenuates neuroinflammation,&#xD;
      reduces cerebral edema, and improves functional and cognitive performance. The investigators&#xD;
      seek to establish if these targets are modified in humans with ICH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel 1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, study staff, analytic staff (to patient identifiers), sponsor staff (only to treatment allocation, unblinded to enable handling and review of data and drug accountability prior to database lock)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the proportion of all cause-morality between arms</measure>
    <time_frame>7 days post-randomization</time_frame>
    <description>Assess the safety and tolerability of MW189 for patients as determined by the rate of death during the treatment period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MW189</intervention_name>
    <description>MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of spontaneous, non-traumatic ICH.&#xD;
&#xD;
          -  10 mL ≤ ICH ≤ 60 mL (confirmed via diagnostic and stability CT scans utilizing&#xD;
             volumetric assessment)&#xD;
&#xD;
          -  Participants receiving anticoagulants are eligible upon reversal and stability within&#xD;
             24hrs after onset of ICH symptoms&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Able to receive first dose of test article ≤ 24h after onset of ICH symptoms&#xD;
&#xD;
          -  NIHSS score ≥ 2 at randomization or Glasgow Coma Scale ≥ 5 at randomization&#xD;
&#xD;
          -  Controlled blood pressure (systolic BP &lt; 180 mm Hg) at randomization.&#xD;
&#xD;
          -  Premorbid magnetic resonance spectroscopy (mRS) of 0-2&#xD;
&#xD;
          -  Has adequate venous access&#xD;
&#xD;
          -  No planned surgical intervention except EVD&#xD;
&#xD;
          -  Written informed consent from the patient or legally authorized representative (LAR)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable hematoma defined as &gt; 6 mL increase as compared to previous CT volume taken&#xD;
             at least 6 hours apart within 24 hrs after onset of ICH symptoms.&#xD;
&#xD;
          -  Anticipated neurosurgical evacuation by open surgery or minimally invasive surgery&#xD;
             with or without Alteplase (EVD allowed).&#xD;
&#xD;
          -  Uncontrolled temp &gt;38.5˚C at enrollment.&#xD;
&#xD;
          -  Signs of intracranial infection or emergence of a systemic infection&#xD;
&#xD;
          -  Is pregnant or lactating&#xD;
&#xD;
          -  Signs of liver and kidney chronic disease (i.e. creatinine &gt;2, bilirubin &gt; 3,&#xD;
             receiving dialysis)&#xD;
&#xD;
          -  Non-reversible bleeding diathesis&#xD;
&#xD;
          -  Used any chronic immunosuppressants or chronic anti-inflammatory drugs (excluding&#xD;
             low-dose aspirin), by any route of administration within the past 7 days.&#xD;
&#xD;
          -  Anticipated withdrawal of life-sustaining therapies within the first week after&#xD;
             admission.&#xD;
&#xD;
          -  In the opinion of the investigator, patient has any contraindication to the planned&#xD;
             study assessments.&#xD;
&#xD;
          -  In the opinion of the investigator, patient has a condition that could interfere with&#xD;
             the proposed treatment or unacceptably increase the individual's risk by participating&#xD;
             in the study.&#xD;
&#xD;
          -  Concomitant enrollment in another acute interventional study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Van Eldik</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Hanley</last_name>
    <phone>(410) 361-7999</phone>
    <email>dhanley@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angeline Nanni</last_name>
    <phone>(667) 208-8525</phone>
    <email>ananni2@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Wendy Ziai, MD</last_name>
      <phone>410-955-7481</phone>
      <email>weziai@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniel F Hanley, Jr</last_name>
      <phone>(410)6146996</phone>
      <email>dhanley@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wendy Ziai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracerebral hemorrhage</keyword>
  <keyword>MW01-6-189WH</keyword>
  <keyword>MW189</keyword>
  <keyword>Radiographic perihematomal edema</keyword>
  <keyword>Neuroinflammation</keyword>
  <keyword>Cerebral edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

